Review
Pharmacology & Pharmacy
Neil Tanday, Peter R. Flatt, Nigel Irwin
Summary: GLP-1, as an important incretin hormone, has made significant progress in drug development and clinical application, offering a wide range of metabolic benefits. With the clinical approval and continuous evolution of GLP-1 receptor ligands, it is expected that GLP-1 has great potential in treating diseases beyond diabetes and obesity.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Review
Endocrinology & Metabolism
Qiming Tan, Seun E. Akindehin, Camila E. Orsso, Richelle C. Waldner, Richard D. DiMarchi, Timo D. Mueller, Andrea M. Haqq
Summary: GLP-1 has been extensively studied as a therapeutic target for obesity and type 2 diabetes. Improvement in the pharmacokinetic profile of GLP-1R agonists and the recent clinical success of GIPR agonists have opened up new possibilities for the treatment of obesity and diabetes.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Psychiatry
Daniel H. Cooper, Ranuk Ramachandra, Felicia Ceban, Joshua D. Di Vincenzo, Taeho Greg Rhee, Rodrigo B. Mansur, Kayla M. Teopiz, Hartej Gill, Roger Ho, Bing Cao, Leanna M. W. Lui, Muhammad Youshay Jawad, Juliet Arsenault, Gia Han Le, Diluk Ramachandra, Ziji Guo, Roger S. McIntyre
Summary: This study aimed to investigate whether GLP-1 receptor agonists can be used prophylactically to lower the risk of incident depression in patients with diabetes mellitus (DM). The results showed mixed findings regarding the effect of GLP-1 receptor agonists on lowering the risk of incident depression. Further research is needed to better understand the potential neuroprotective effects of GLP-1 receptor agonists on depression in patients with DM.
JOURNAL OF PSYCHIATRIC RESEARCH
(2023)
Review
Endocrinology & Metabolism
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, Andreas F. H. Pfeiffer
Summary: Incretin hormones GIP and GLP-1 play a significant role in insulin secretion and glucose tolerance in the gut-endocrine pancreas axis. They also have additional effects on bone remodelling, lipid storage, gastric emptying, and may provide benefits for cardiovascular complications and neurodegenerative disorders. Recent research on GIP/GLP-1 receptor co-agonists has renewed interest in the potential therapeutic applications of incretin hormones.
DIABETES OBESITY & METABOLISM
(2021)
Article
Biochemistry & Molecular Biology
Bo Ahren
Summary: In this study, the contribution of GIP and GLP-1 to insulin response to oral glucose in female mice was investigated using receptor antagonists. It was found that both GIP and GLP-1 are required for a normal incretin effect in female mice, and no other incretin hormone is likely present in this species.
Article
Endocrinology & Metabolism
Heike Jung, Sascha R. Tittel, Nanette C. Schloot, Elke Heitmann, Thorsten Otto, Jeremie Lebrec, Marianne Pavel, Stefanie Lanzinger
Summary: This study aimed to investigate the clinical characteristics, treatment patterns, and persistence of GLP-1 RA in patients with type 2 diabetes. The results showed an increased duration of GLP-1 RA therapy over time and a decrease in HbA1c levels compared to baseline.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Chia-Hung Lin, Yun-Shien Lee, Yu-Yao Huang, Chi-Neu Tsai
Summary: The methylation status of the VTRNA2-1 promoter is associated with glycemic response to GLP-1 analog therapy in patients with poorly controlled type 2 diabetes mellitus.
BMJ OPEN DIABETES RESEARCH & CARE
(2021)
Article
Endocrinology & Metabolism
Sarah M. Gray, Andrew L. Hoselton, Radha Krishna, Cris A. Slentz, David A. D'Alessio
Summary: GLP-1r signaling contributes to insulin secretion during alpha-cell activation, independent of increased circulating GLP-1, and may be affected by DPP4 inhibition.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Signe Foghsgaard, Louise Vedtofte, Emilie S. Andersen, Emilie Bahne, Camilla Andreasen, Anne L. Sorensen, Julie L. Forman, Elisabeth R. Mathiesen, Jens A. Svare, Tine D. Clausen, Peter Damm, Jens J. Holst, Filip K. Knop, Tina Vilsboll
Summary: A 52-week treatment with liraglutide improved glucose tolerance, fasting plasma glucose, glycated hemoglobin, and bodyweight in women with overweight/obesity and previous gestational diabetes mellitus. However, the effects disappeared after a 1-week drug wash-out.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Chuanmin Bai, Yujun Wang, Zhi Niu, Yaxin Guan, Jingshan Huang, Xin Nian, Fan Zuo, Juan Zhao, Tsutomu Kazumi, Bin Wu
Summary: The study found that adipokines induced by different regional fat depots were significantly higher in the supernatant of HepG2 cells than in the HepG2 group, with visceral adipose tissue releasing more adipokines than subcutaneous adipose tissue. Additionally, exenatide significantly inhibited the release of these adipokines. The research also revealed that different fat depots affect the IRS2/PI3K/Akt2 insulin signaling pathway of hepatocytes. Exenatide may improve hepatic insulin resistance by inhibiting adipokines and regulating the expression of key proteins in the IRS2/PI3K/Akt2 pathway.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Nikolaus Marx, Mansoor Husain, Michael Lehrke, Subodh Verma, Naveed Sattar
Summary: Multiple large cardiovascular outcome trials have shown that SGLT2 inhibitors and GLP-1 receptor agonists significantly reduce cardiovascular disease risk in patients with type 2 diabetes, including major adverse cardiovascular events and heart failure. These drugs have received strong recommendations in diabetes and cardiology guidelines, but their usage remains low.
Article
Endocrinology & Metabolism
Neil Tanday, Andrew English, Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin
Summary: The combined activation of GLP-1 and CCK1 receptors through [Lys(12)Pal]Ex-4/CCK showed enhanced beneficial effects on pancreatic beta-cells, leading to improved insulin secretion and glucose homeostasis in vitro and in mice models. This hybrid peptide therapy also resulted in reductions in energy intake and body weight, as well as improvements in glucose tolerance, insulin responsiveness, and pancreatic islet morphology, highlighting its potential for treating obesity-related diabetes.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Jonathan M. Wilson, Yanzhu Lin, M. Jane Luo, Gary Considine, Amy L. Cox, Lenden M. Bowsman, Deborah A. Robins, Axel Haupt, Kevin L. Duffin, Giacomo Ruotolo
Summary: In a phase 2 trial, tirzepatide reduced HbA1c and body weight dose-dependently in patients with type 2 diabetes, and also decreased several biomarkers associated with cardiovascular risk factors, showing potential positive effects on cardiovascular health.
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Antonio Di Mauro, Dario Tuccinardi, Mikiko Watanabe, Rossella Del Toro, Lavinia Monte, Riccardo Giorgino, Lorenzo Rampa, Giovanni Rossini, Shadi Kyanvash, Andreea Soare, Milena Rosati, Alessandra Piccoli, Nicoli Napoli, Elvira Fioriti, Paolo Pozzilli, Yeganeh M. Khazrai, Silvia Manfrini
Summary: The study compared Mediterranean diet with high-fibre vegetarian diet in terms of hunger-satiety perception in overweight/obese subjects with type 2 diabetes. The Mediterranean diet was found to be more effective in post-prandial plasma glucose homoeostasis and GLP-1 and oxyntomodulin release compared to the high-fibre vegetarian diet, with no significant differences observed in self-reported VAS appetite assessment.
DIABETES-METABOLISM RESEARCH AND REVIEWS
(2021)
Review
Immunology
Syed Faizan Mehdi, Suma Pusapati, Muhammad Saad Anwar, Durga Lohana, Parkash Kumar, Savitri Aninditha Nandula, Fatima Kausar Nawaz, Kevin Tracey, Huan Yang, Derek LeRoith, Michael J. Brownstein, Jesse Roth
Summary: Inflammation is involved in many chronic conditions and stimulates the release of pro-inflammatory cytokines and immune cells. GLP-1 levels are associated with disease severity and can serve as markers of inflammation. Previous studies have investigated the anti-inflammatory properties of oxytocin, hCG, ghrelin, alpha-MSH and ACTH, while the anti-inflammatory effects of GLP-1 have only recently been recognized. GLP-1 has been shown to be beneficial in treating type-2 diabetes, metabolic syndrome, and hyperglycemia by reducing inflammation and cell death.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Surgery
Vance L. Albaugh, Tammy L. Kindel, Steven E. Nissen, Ali Aminian
Summary: Cardiovascular disease remains a significant burden globally and metabolic surgery may reduce mortality in obese patients.
SURGICAL CLINICS OF NORTH AMERICA
(2021)
Letter
Surgery
Vance L. Albaugh, Ali Aminian
SURGERY FOR OBESITY AND RELATED DISEASES
(2022)
Editorial Material
Surgery
Vance L. Albaugh
SURGERY FOR OBESITY AND RELATED DISEASES
(2022)
Review
Endocrinology & Metabolism
Vance L. Albaugh, Yanlin He, Heike Munzberg, Christopher D. Morrison, Sangho Yu, Hans-Rudolf Berthoud
Summary: Bariatric surgery is an effective treatment for obesity and metabolic disease, but limited in availability. Research is needed to understand the molecular mechanisms involved and develop targeted behavioral or pharmacological treatments. Gut-brain communication and its effects on food intake control and energy balance regulation are complex and redundant. Advanced techniques and animal models are necessary for further investigation.
MOLECULAR METABOLISM
(2023)
Meeting Abstract
Endocrinology & Metabolism
Christopher L. Axelrod, Ingeborg M. Langohr, Wagner S. Dantas, R. Leigh Townsend, Vance L. Albaugh, John P. Kirwan, Hans-Rudolf Berthoud
Article
Surgery
Linda Adepoju, Denise Danos, Christian Green, Michael W. Cook, Philip R. Schauer, Vance L. Albaugh
Summary: This study examined trends in postoperative major adverse cardiovascular and cerebrovascular events (MACE) after bariatric surgery from 2012 to 2019 using a national inpatient sample database. The study found that the risk of MACE was lowest for laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB), while open sleeve gastrectomy (SG) and open Roux-en-Y gastric bypass (RYGB) had higher risks. MACE incidence increased over time for SG and RYGB but remained relatively stable for LSG and LRYGB.
SURGERY FOR OBESITY AND RELATED DISEASES
(2023)
Review
Surgery
Robert C. Ross, Yetunde M. Akinde, Philip R. Schauer, Carel W. le Roux, Donal Brennan, Amelia M. Jernigan, Marco Bueter, Vance L. Albaugh
Summary: The obesity pandemic contributes to various diseases including diabetes, cardiovascular disease, and cancer. Metabolic and bariatric surgery is considered the most effective treatment for obesity and may also have a protective benefit in terms of cancer incidence, particularly for endometrial cancer. Gynecologic oncologist visits provide an opportunity to identify patients who may benefit the most from metabolic surgery as a potential treatment for endometrial cancer.
FRONTIERS IN SURGERY
(2022)
Article
Endocrinology & Metabolism
Gunther Wong, Erica M. Garner, Sahar Takkouche, Matthew D. Spann, Wayne J. English, Vance L. Albaugh, Gitanjali Srivastava
Summary: Combination anti-obesity medications may be needed to achieve optimal weight loss results to treat post-operative weight regain.
OBESITY SCIENCE & PRACTICE
(2023)
Article
Endocrinology & Metabolism
Vance L. Albaugh, Christopher Axelrod, Kathryn P. Belmont, John P. Kirwan
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
(2023)
Editorial Material
Surgery
Vance L. Albaugh
SURGERY FOR OBESITY AND RELATED DISEASES
(2023)
Editorial Material
Nutrition & Dietetics
Christopher J. Lynch
AMERICAN JOURNAL OF CLINICAL NUTRITION
(2023)
Article
Surgery
Robert C. Ross, Yanlin He, R. Leigh Townsend, Philip R. Schauer, Hans-Rudolph Berthoud, Christopher D. Morrison, Vance L. Albaugh
Summary: This study investigated the effects of bariatric surgery on obesity using a mouse model, focusing on the neuro-hormonal mechanisms. The results showed that nutrient signals in the duodenum significantly increased after bariatric surgery. This study suggests that bariatric surgery may alleviate obesity by altering cellular signaling mechanisms in the duodenum.
Article
Endocrinology & Metabolism
Christopher L. Axelrod, Ingeborg Langohr, Wagner S. Dantas, Elizabeth C. Heintz, Bolormaa Vandanmagsar, Shengping Yang, Elizabeth R. M. Zunica, R. Leigh Townsend, Vance L. Albaugh, Hans-Rudolf Berthoud, John P. Kirwan
Summary: Obesity is a driver of non-alcoholic fatty liver disease, and interventions that decrease body weight, such as bariatric surgery and/or calorie restriction, may serve as effective therapies. This study compared the effects of Roux-en-Y gastric bypass surgery and calorie restriction on hepatic function in mice with obesity and NAFLD. The results showed that gastric bypass surgery reduced hepatic lipid content and adiposity while increasing energy expenditure and lean body mass. Gastric bypass surgery also activated enterohepatic signaling and genes regulating hepatic lipid homeostasis.
Review
Surgery
Salvatore Docimo Jr, Laura Aylward, Vance L. Albaugh, Cheguevara Afaneh, Sofiane El Djouzi, Mohamed Ali, Maria S. Altieri, Jonathan Carter
SURGERY FOR OBESITY AND RELATED DISEASES
(2023)
Article
Surgery
Robert C. Ross, Elizabeth C. Heintz, Elizabeth R. M. Zunica, R. Leigh Townsend, Amanda E. Spence, Philip R. Schauer, John P. Kirwan, Christopher L. Axelrod, Vance L. Albaugh
Summary: This study investigated the effects of MBS surgery on intestinal mitochondrial function in mice. The results showed that ileal interposition decreased mitochondrial volume in the proximal intestinal mucosa of mice, while respiration remained unchanged. Further studies are needed to understand the underlying causes of these mitochondrial changes.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2023)